Role of Molecular Targeted Therapeutic Drugs in Treatment of Breast Cancer: A Review Article
- PMID: 37228871
- PMCID: PMC10205396
- DOI: 10.1055/s-0043-57247
Role of Molecular Targeted Therapeutic Drugs in Treatment of Breast Cancer: A Review Article
Abstract
Breast cancer is a multifactor, multistage, and heterogeneous disease. Systemic treatment of breast cancer has changed significantly over the last decade. With a better knowledge of the pathogenesis, researchers and scientists have discovered numerous signaling pathways and synonymous therapeutic targets in breast cancer. Because of the molecular nature of breast cancer, which makes it difficult to understand, previous attempts to treat or prevent it have failed. However, recent decades have provided effective therapeutic targets for treatment. In this review, literature or information on various targeted therapy for breast cancer is discussed. English language articles were explored in numerous directory or databases like PubMed, Web of Sciences, Google Scholar, ScienceDirect, and Scopus. The important keywords used for searching databases are "Breast cancer," "Targeted therapy in breast cancer," "Therapeutic drugs in breast cancer," and "Molecular targets in breast cancer."
Keywords: breast cancer; molecular targets in breast cancer; precision medicine in breast cancer; targeted therapy in breast cancer; therapeutic drugs in breast cancer.
The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. ( https://creativecommons.org/licenses/by/4.0/ ).
Conflict of interest statement
Conflict of Interest None declared.
References
-
- Sledge G W, Jr, Miller K D. Exploiting the hallmarks of cancer: the future conquest of breast cancer. Eur J Cancer. 2003;39(12):1668–1675. - PubMed
-
- Ingvarsson S. Genetics of breast cancer. Drugs Today (Barc) 2004;40(12):991–1002. - PubMed
-
- Kenemans P, Verstraeten R A, Verheijen R HM. Oncogenic pathways in hereditary and sporadic breast cancer. Maturitas. 2004;49(01):34–43. - PubMed
-
- Eniu A. Integrating biological agents into systemic therapy of breast cancer: trastuzumab, lapatinib, bevacizumab. J BUON. 2007;12 01:S119–S126. - PubMed
-
- Modi S, D'Andrea G, Norton L. A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. Clin Breast Cancer. 2006;7(03):270–277. - PubMed
Publication types
LinkOut - more resources
Full Text Sources